Biological Oncology

Adcetris

Payments companies reported to CMS as associated with Adcetris. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$3.7Massociated payments (2023-2025)

8,533clinicians with associated payments

5companies reporting

By year

2023 $2.1M

2024 $779K

2025 $820K

Payments reported as associated with Adcetris, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Hematology & Oncology $1.7M

Medical Oncology $948K

Hematology (Internal Medicine) $400K

Nurse Practitioner $133K

Family $125K

Oncology (Registered Nurse) $67K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Adcetris

These are the largest totals companies reported as associated with Adcetris. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Andrew Whiteley	Dallas, TX	Medical Oncology	$133,134.66
Moshe Levy	Dallas, TX	Medical Oncology	$132,930.23
Raghuveer Ranganathan	Los Angeles, CA	Hematology & Oncology	$122,377.19
Kevin Rakszawski	Hershey, PA	Hematology & Oncology	$109,307.17
Joshua Brody	New York, NY	Medical Oncology	$86,751.80
Vincent Herrin	Jackson, MS	Hematology (Internal Medicine)	$80,835.78
Rushang Patel	Orlando, FL	Medical Oncology	$80,329.04
Ahmed Sawas	New York, NY	Hematology (Internal Medicine)	$78,872.66
Ann Mcneill	Neptune, NJ	Oncology (Registered Nurse)	$66,949.12
Timothy Fenske	San Antonio, TX	Hematology & Oncology	$65,187.72

Prescribed Adcetris?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.